Dow Jones 13766.70 -48.86 1:21 pm PDT, September 20, 2007 NASDAQ 2654.29 -12.19 For info, visit access.smallcapnetwork.com S & P 500 1518.75 -10.28 Change your subscription status here Russell 2000 809.76 -7.64 VOLUME 07 : ISSUE 88 Something's Still Coming  I know I promised all of you a new trading idea on Friday. However, after thinking a little more about it, I've decided to wait until Saturday morning to send it out. I know for a lot of you a 40+ hour workweek can make it tough to read and process one more thing late in the day on a Friday. I'd rather introduce you to this company when you're relaxed on Saturday...so you can prop your feet up and really immerse yourself in the newsletter, as well as the short video. And believe me, this is a stock worth making this little accommodation for - I think it deserves everyone's full attention. See you Saturday morning. In the meantime...   BioCurex: The Other Shoe Has Dropped They say when it rains it pours, but when it's good news, I guess that's a good thing. Just two days after we heard from BioCurex (OTCBB: BOCX) about early success with their rapid 'point of care' cancer screening tests, we're now hearing from them about the big enchilada...the lab-based version of their cancer detection test. Abbott Laboratories (NYSE: ABT) has - for the first time we're aware of - publicly presented successful use of BioCurex's RECAF technology using Abbott's diagnostic instruments.  For those of you who have been following the BioCurex/RECAF story closely, you may immediately understand the magnitude of this news. For others, let me catch you up with the condensed version of the tale.  RECAF is a cancer marker, meaning it can pinpoint if or where there are cancerous cells, and not show a 'positive' test result if there are no cancerous cells. BioCurex has been developing the RECAF detection technology for a few years now. The progress and results so far have been very promising, so much so that Abbott became a licensee for the test even though the test is not yet completely ready for use. In fact, Abbott has been working with BioCurex in an effort to get the test ready. (What does that tell you?)  As it became clear the RECAF test had merit, it was also realized the format for doing the underlying lab work was not ideal - RECAF was originally designed to use radioimmunoassay (radioactivity-based) to determine whether or not cancerous cells were present. Most medical labs, however, have started using chemiluminescent assays (light-based). In order to have wide appeal, a major format change would have to take place...and it did. (For more details on the assay issue and BioCurex's adaptation, click here to go back to our October 25th, 2006 edition by clicking here.)  Abbott, despite being a licensee as well as major supplier of the equipment used in most diagnostic labs, had been fairly quiet on the topic, until now. At this year's International Society for Oncodevelopmental Biology and Medicine conference - going on now - Abbott Laboratories has finally publicized what they've been doing with BioCurex's creation.  The evidence comes in the form of two presentations at the conference. The first one explains how the chemiluminescent assay can and does distinguish between cancerous and non-cancerous serum. The Abbott-built device scored a 0.954 out of a possible 1.00, in terms of successfully identifying positive and negative samples. The second presentation discusses the ideal kind of tube to use for the purpose of performing a RECAF test in a diagnostic lab. As it turns out, the 'best' collection device to use for RECAF testing is also the most common kind. The full press release is at the bottom of this newsletter.  Neither Abbott nor BioCurex has specifically made the following points, but there are some observations that immediately came to my mind as I went through this news...  1) This was Abbott doing the testing and presenting - not BioCurex. 2) While BioCurex is a small cap, Abbott is a major name in the diagnostic world...they own 1/3 of the diagnostics market. 3) The test seems to work as far as I can see through my non-biotechnician eyes. A score of 0.954 out of 1.00 is a grade of 95.4% to me...which is outstanding when it comes to medical diagnostic metrics. 4) The test can be performed by the vast majority of labs.  Maybe it's just me, but doesn't this address all of the major concerns the market has had about BioCurex? I have to think this is a major leap towards monetization of the test. That's not to say it'll be ready and on the market tomorrow morning, but it may be sooner than anybody thinks.  As for the stock, you know how these things work. The market tends to price a stock at what it thinks it will be worth in the future - not what it's worth now. As such, I think this could be one heck of a bullish jolt. In fact, the rumors already did push the stock upward to some degree...that's why we jumped on it back on September 4th. It's been rolling since then (and even before then), and I suspect this news will put the pedal to metal. Wanna' get on for the ride?    Titan Global Knocks On Door Of New Highs  In a blog entry Wednesday I mentioned how Titan Global (OTCBB: TTGL) looked like it had fallen back all it was going to, and was starting to drop a few bullish hints. Specifically, a key Fibonacci retracement line had been met, and we were starting to see higher highs and higher lows again.  If you were waiting for a second chance on TTGL, I really hope you read yesterday's comments. Why? The stock is off to the races (again) today, up quite firmly on good volume. In fact, it reached as high as $2.20 on an intra-day basis. That $2.20 level is significant it seems; that's where TTGL topped on September 6th as well. When and if that resistance is breached, I won't be a bit surprised to see another major short-term rally.  At last look, this suggested idea is up more than 70% above our pick price of $1.21. Don't forget though...our suggested target is still $3.00.  Anyway, here's the BioCurex news...    Source: BioCurex, Inc. BioCurex and Abbott Jointly Present RECAF Results at International Cancer Congress  RICHMOND, British Columbia, September 20, 2007 -- BioCurex Inc. (OTCBB: BOCX) -- today announced the acceptance of two presentations submitted to the International Society for Oncodevelopmental Biology and Medicine (ISOBM). The presentations document two RECAF studies involving joint initiatives with the University of Munich, Germany and Abbott.  The first presentation entitled "CHEMILUMINESCENT ASSAY (CIA) FOR THE RECEPTOR OF ALPHA FETOPROTEIN (RECAF) TO SEPARATE CANCER FROM NORMAL SERA" demonstrates the results obtained with the assay format used in several automated instruments including the Abbott ArchitectTM. 68 breast, gastric and other types of cancers were compared to 52 normal patients and the AUC1 scoring obtained was 0.954 (a perfect discrimination between cancer and normal samples has a score of 1.0). Similar results were independently obtained in our Licensee's facility for prostate cancer samples.  The second study was done in collaboration with our Licensee and the University of Munich to determine the best type of specimen collecting tube for RECAF testing in a clinical laboratory environment. There is an extensive variety of blood collecting tubes available. These are vacuum tubes that contain different combinations of chemicals intended to accelerate clotting in various ways, prevent clotting, separate the clot from the serum, etc. Some of them are not compatible with certain assays and therefore it is always necessary before the commercialization of a serum test to find out which tubes are chemically compatible. The results presented indicate that the RECAF assay is compatible with the most commonly used serum collection tube types.  Ricardo Moro, President and CEO stated: "These presentations to the ISOBM validate our joint efforts to develop the RECAF assay in the chemoluminescence format used by high throughput automated instruments. These results correlate with those in previous presentations and provide additional support for the effectiveness of the RECAF technology. This presentation will, no doubt, trigger a positive response from the scientific community and demonstrate to our shareholders that we are steadily progressing toward the commercialization of the technology. Developing the foundations of a test that has the potential to significantly change the way we diagnose cancer takes time and focus. The team effort with this major diagnostic company has resulted in very significant progress - part of which will be presented at this Meeting. We are getting closer and closer to the commercialization of a cancer test that has the potential to be used for screening patients in much the same way a blood sugar or cholesterol reading is requested as part of a routine blood test. This is extremely valuable, both from the medical as well as the commercial point of view.  (1 AUC is the Area Under the Curve of a statistic test called Receiver Operating Characteristic or ROC. For more information go to: http://en.wikipedia.org/wiki/Receiver_operating_characteristic.) About The International Society of Oncodevelopmental Biology and Medicine (ISOBM):  The ISOBM originated in the early 1970's from the International Research Group for Carcinoembryonic Proteins. Since then the society has grown to cover wider aspects of research in oncodevelopmental / oncofetal biology. The society also organizes a series of Antibody Workshops. These workshops provide a practical focus on tumor markers in all types of cancer.  About our Licensee:  BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAFTM Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAFTM has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. (http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0030.htm)  About BioCurex:  BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.  To read more about the Company, please visit the News section in our web site (www.biocurex.com).  Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.  Contact:  Terry Johnston  BioCurex, Inc.  Tel: (866) 884-8669  or +1 604-267-3041   We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Email the Editor If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 CEL-SCI Announces Progress For Multi-Purpose Vaccine Adjuvant With all the talk about CEL-SCI's (AMEX: CVM) Multikine cancer treatment, it's easy to forget they're also working on a vaccine adjuvant platform that could ultimately be effective against several types of infections....including hepatitis B, malaria, herpes, and encephalitis, just to name a few. The name of the adjuvant is CEL-1000. If it rings a bell, it may be because this small cap biotech company's CEL-1000 technology really came to light in early 2006 when it was realized it could be an effective tool in the war against the bird flu.  On Monday, CEL-SCI updated the market on CEL-1000's status by releasing details about research done using the vaccine adjuvant against the hepatitis B virus. In a lab setting, it was found to increase the antibody signal in a mouse by 40% by the 28th day of observation. The study also determined what may be the ideal time of dosage, and degree of dosage.  The 'bigger picture' implication is simple enough...CEL-1000 continues to gain validity as a broad vaccine adjuvant. As more research refines how CEL-1000 can and should be used, the potential appeal to the market expands.  For the details of the news, click here.  As for CVM shares, the patient went into a critical status this summer, but appears to have stabilized over the last month. It finally looked like CVM might get something going in April. Then between May and August, we saw shares slide from a peak of $1.08 to a low of $0.57. Since hitting $0.57 though, we've started to see the waters being tested again. Specifically, we're not seeing a string of lower lows anymore. In fact, the 50 day line was tested as resistance three times over the last three weeks. So, clearly somebody is interested.  As for whether or not I think the worst is over, let's just say I'm keeping a close eye on CVM for that possibility. The downtrend has stopped and a wedge has formed. The wedge will have to close up sometime, and force this chart out of its confines. That could be good or bad (bullish or bearish), but if it's bullish I want to be ready. For me, the 50 day line may be the make-or-break point.  To see a chart, click here. Subscribe Information is power and timely information is profitable. Become informed and profit from Small Cap Network Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the Small Cap Network Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the Small Cap Network Member List. Receiving the Small Cap Network Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the Small Cap Network recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the Small Cap Network Newsletter, simply follow the instructions located at the bottom of every Small Cap Network Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCN") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCN is owned and operated by TGR Group, LLC ("TGR"). All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCN. To the degrees enumerated herein, SCN should not be regarded as an independent publication.  Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://access.smallcapnetwork.com/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts.  TGR Group LLC has been paid a fee of $30,000 cash by Titan General for coverage of the company. In addition, TGR Group LLC has been pledged a fee of 100,000 warrants convertible at $1 into restricted shares by Trilogy Capital for coverage of the company.  TGR Group LLC has been paid a fee of $25,000 and 150,000 shares of newly issued restricted stock by Cel-Sci for coverage of the Company. The aforementioned 150,000 restricted shares have become free trading under SEC rule 144. Additionally, back in November of 2002, TGR Group LLC was paid a fee of $25,000 and 250,000 shares of newly issued restricted stock of Cel-Sci for coverage of the company until November of 2003. The aforementioned 250,000 restricted shares became free trading under SEC rule 144 and were sold in the open market prior to the company entering into a new contract agreement with TGR Group in February of 2006.  In October of 2003, TGR Group LLC was paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the Company. Under SEC Rule 144, all one million issued restricted shares have been eligible for sale into the public market since October of 2004. In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares and on July 1, 2006 TGR entered into another extended agreement with Biocurex for an additional 100,000 shares of newly issued, restricted stock. From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.  TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed.  All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCN is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.  The profiles, critiques, and other editorial content of SCN may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.  THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR.  We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.